Study summary · 2026 · Implementation
Hypertension RPM costs and provider return on investment
Provider profitability was sensitive to staffing costs, reimbursement and patient participation.
Summary by Vironix Health · Source review: November 11, 2026
How we select and interpret evidence
Original publication
Donglan S Zhang; Laure Millet; Brandon K Bellows; Sarah Lee; Devin Mann
NYU Grossman Long Island School of Medicine; NYU Grossman School of Medicine; NYU Langone Health; Columbia University Irving Medical Center
Journal of Telemedicine and Telecare · Online: · Issue: September 2026
2026 journal article superseding the 2025 medRxiv preprint (PMID 39974005). · Summary limited to the accessible abstract.
What was studied
- Design
- Implementation
- Population
- One cardiology division's hypertension RPM program
- Sample
- Single-program costing study; patient denominator not stated in abstract
- Intervention
- Home BP monitoring and telehealth services
- Comparator
- Program costs versus estimated reimbursement
- Follow-up
- Cost observations March–June 2024; per-patient horizon not specified in journal abstract
- Setting
- United States; NYU Langone Health
Methods
Observation, surveys and micro-costing using 2024 prices and estimated Medicare reimbursement.
Findings
The abstract reports a positive average provider ROI, but sensitivity estimates included losses; data review was the largest reported cost component.
Limitations
Single-center financial analysis, not a causal outcomes or payer-savings study. This summary is limited to the journal abstract; it does not use preprint-only details.
What this means for care delivery
Use local workload and payment assumptions when evaluating sustainability; historical estimates are not current billing guidance.